The deal with Tubulis gives Gilead access to the German biotech's ADC technology platform, designed to make ADCs more stable, ...

Enhertu won its initial China nod in early 2023 as a treatment for previously treated HER2-positive breast cancer and later ...

The deal with Tubulis will help Gilead regain its footing in the ADC space following the withdrawal of Trodelvy in bladder ...

GILD and Germany-based Tubulis collaborate to discover and develop an antibody-drug conjugate against a solid tumor target.

GSK has made another trip to China to build out its antibody-drug conjugate (ADC) pipeline, returning with an option on a ...

Sanofi just made its largest investment thus far in China. The company has committed just over $1 billion to build a new ...

Kelun-Biotech has become the second drugmaker to bring a TROP2-directed antibody-drug conjugate to regulatory approval, ...

Sac-TMT, also known as SKB264 or MK-2870, represents the first asset in Kelun’s multitarget, multibillion-dollar ADC ...

Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $75 ...

Trodelvy shows effectiveness in treating metastatic triple-negative breast cancer, supported by real-world data. Common side effects include neutropenia, anemia, and fatigue, but are generally ...

Trodelvy's FDA approval for bladder cancer was rescinded due to unmet survival endpoints in the TROPICS-04 study. The drug remains approved for certain breast cancer treatments, highlighting its ...

In February, it announced a collaboration with California’s Gilead Sciences to develop the cancer drug Trodelvy in a deal worth up to $210mn. Trodelvy is already approved to treat some cancers ...